Why the study?
Does platelet-activating factor inhibit Cu(II) induced oxidation of LDL in vitro?
Does platelet-activating factor inhibit Cu(II) induced oxidation of LDL in vitro?
Platelet-activating factor and its short-chain analogs effectively inhibit Cu(II)-induced LDL oxidation in vitro, suggesting factors beyond natural antioxidants influence LDL oxidation.
Indicates factors beyond antioxidants modulate LDL oxidation; hypothesis-generating for PAF in atherogenesis.
Oxidatively modified low-density-lipoprotein (LDL) might contribute to the atherosclerotic process. This study was performed to examine an effect of platelet-activating factor (PAF) and of synthetic PAF analogs on Cu(II) induced oxidation of LDL in vitro: The D- and L-isomers of PAF and analogs with short-chain sn-2-substituents, 1-O-alkyl-2-butyryl-sn-glycero-3-phosphocholine and 1-O-alkyl-2-heptanoyl-sn-glycero-3-phosphocholine, were found to be the most effective inhibitors of LDL oxidation. Oxidation was inhibited completely at PAF concentrations above 100 microM. Lyso-PAF and analogs carrying longer chains at the sn-2 position were less effective. These results thus provide evidence for the involvement of other parameters in LDL oxidation beyond the content of natural antioxidants like vitamin E and beta-carotene.
No takes yet. Share an insight, caveat, or question.
Deigner et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: